About
Immunicum AB develops cancer immunotherapies, focusing on therapeutic vaccines for patients with existing diseases. The company utilizes technology platforms including Combig, Intuvax@, Subcuvax@, and CD70 to create treatments targeting kidney cancer and liver cancer. Immunicum AB's products are administered to patients to delay or stop tumor growth, shrink tumors, prevent relapse, or eliminate cancer cells that other treatments could not remove. The firm's therapeutic approach is designed for already sick patients, differentiating it from preventive vaccines. The company operates with 11 full-time employees and has a history of developing immunotherapies for cancer and infectious diseases. Immunicum AB's business model centers on creating and advancing therapeutic cancer vaccines through its various technology platforms. The firm's projects specifically address kidney cancer and liver cancer, leveraging its Combig, Intuvax@, Subcuvax@, and CD70 platforms to develop targeted treatments. Immunicum AB's revenue streams are derived from the development and potential commercialization of its immunotherapy products. The company's focus on therapeutic vaccines for cancer patients means its primary customers are healthcare providers and institutions treating cancer patients. The firm's technology platforms are integral to its product development, with each platform supporting specific treatment approaches for kidney and liver cancer.
Annual results
Reported figures, SEK
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | — | -113M | — | — |
| 2024 | — | -128M | — | — |
| 2023 | — | -101M | — | — |
| 2022 | 1.0M | -138M | -13800.0% | — |
| 2021 | — | -133M | — | — |
IMMU.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Mendus AB (publ) are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.